Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Mylan to pay $465m in settlement over EpiPen

US drug manufacturer Mylan has agreed a US $465m settlement with the US Department of Justice in response to allegations that it overcharged the healthcare programme Medicaid for its anaphylaxis treatment EpiPen (epinephrine).

Although the pen is marketed as a branded product, Mylan was accused of classifying the product as a generic sale which meant it reduced the rebates that it had to pay to Medicaid under the terms of the drug rebate programme. 

In a statement, the US Department of Justice said that the settlement was made to resolve claims that the company “violated the False Claims Act by knowingly misclassifying EpiPen as a generic drug to avoid paying rebates owed primarily to Medicaid”.

Acting US attorney William D Weinreb said: “Taxpayers rightly expect companies like Mylan that receive payments from taxpayer-funded programs to scrupulously follow the rules. We will continue to protect the integrity of Medicaid and ensure a level playing field for pharmaceutical companies.”

In a statement, Mylan stressed that the settlement “does not contain an admission or finding of wrongdoing”.

Mylan’s chief executive officer Heather Bresch said: “Bringing closure to this matter is the right course of action for Mylan and our stakeholders to allow us to move forward.”

As part of the deal, Mylan has signed a Corporate Integrity Agreement with the Office of Inspector General of the Department of Health and Human Services and agreed to reclassify EpiPen auto-Injector for purposes of the Medicaid drug rebate program ‘and pay the rebate applicable to innovator products effective as of April 1, 2017’.

The settlement was signed by two of Mylan NV subsidiaries — Mylan Inc. and Mylan Specialty LP.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2017.20203440

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Epipen auto injector

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.